(Q50653878)

17 March 2018

title

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. (English)

1 reference

17 March 2018

main subject

chronic myeloid leukemia

0 references

1 reference

1

1 reference

17 March 2018

Andreas Hochhaus

13

1 reference

17 March 2018

Claudia Haferlach

3

object named as

Claudia Haferlach

1 reference

17 March 2018

4

Susanne Schnittger

1 reference

17 March 2018

6

Alice Fabarius

1 reference

17 March 2018

5

Markus Pfirrmann

0 references

author name string

Benjamin Hanfstein

2

1 reference

17 March 2018

Markus Pfirrmann

5

1 reference

17 March 2018

Brigitte Schlegelberger

7

1 reference

17 March 2018

Susanne Saußele

8

1 reference

17 March 2018

Christian T Dietz

9

1 reference

17 March 2018

Philipp Erben

10

1 reference

17 March 2018

Rüdiger Hehlmann

11

1 reference

17 March 2018

Joerg Hasford

12

1 reference

17 March 2018

Martin C Müller

14

1 reference

17 March 2018

publication date

22 June 2014

1 reference

17 March 2018

Journal of Cancer Research and Clinical Oncology

published in

1 reference

17 March 2018

volume

140

1 reference

17 March 2018

issue

11

1 reference

17 March 2018

page(s)

1965-1969

1 reference

17 March 2018

https://scigraph.springernature.com/pub.10.1007/s00432-014-1746-8

exact match

0 references

cites work

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1746-8

Standardized definitions of molecular response in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1746-8

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1746-8

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1746-8

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1746-8

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1746-8

The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1746-8

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1746-8

Harmonization of molecular monitoring of CML therapy in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-014-1746-8

Exclusion of chromosomal mosaicism: tables of 90%, 95% and 99% confidence limits and comments on use

21 January 2018

1 reference

12 December 2020

Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML St

1 reference

12 December 2020

Monitoring disease response to tyrosine kinase inhibitor therapy in CML.

1 reference

12 December 2020

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

1 reference

12 December 2020

Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction

1 reference

12 December 2020

10.1007/S00432-014-1746-8

Identifiers

DOI

1 reference

17 March 2018

PubMed ID

24952896

1 reference

17 March 2018